# Lexeo Therapeutics Discusses PKP2 Arrhythmogenic Cardiomyopathy Treatment Gap

> Lexeo Therapeutics highlights unmet need in PKP2 arrhythmogenic cardiomyopathy with no approved treatments.
- Title: Lexeo Therapeutics Discusses PKP2 Arrhythmogenic…
- Summary: Lexeo Therapeutics highlights unmet need in PKP2 arrhythmogenic cardiomyopathy with no approved treatments. Lexeo Therapeutics states PKP2 arrhythmogenic…
- Keywords: lexeo therapeutics, pkp2, arrhythmogenic cardiomyopathy, clinical assessment, unmet need, rare disease, money, business, Lexeo, Therapeutics, Discusses, Arrhythmogenic
- Source: Seekingalpha — https://seekingalpha.com/article/4956045-lexeo-therapeutics-inc-lxeo-discusses-clinical-assessment-and-unmet-need-in-pkp2
- Author: SA Transcripts
- Published: 2026-10-21T23:54:02+00:00
- Read time: 1 min
- Topics: lexeo therapeutics, pkp2, arrhythmogenic cardiomyopathy, clinical assessment, unmet need, rare disease, money, business
## Lexeo Therapeutics
Lexeo Therapeutics discusses clinical assessment and unmet need in PKP2 arrhythmogenic cardiomyopathy.
## PKP2 Arrhythmogenic Cardiomyopathy
PKP2 arrhythmogenic cardiomyopathy is a serious progressive genetic disease with no approved treatment designed to modify its course.
## Unmet Need
The affected population is larger than those associated with many traditional rare disease gene therapy.
## Key takeaway

Lexeo Therapeutics states PKP2 arrhythmogenic cardiomyopathy has no approved treatments to modify its course.